SCHEMBL604784

SCHEMBL604784

O=C1c2ccccc2C(=O)N1C1CCC(OC2CCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 6/20 0.44
TSHR P16473 3/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
CHRM2 P08172 1/20 0.41
OPRM1 P35372 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
IKZF3 Q9UKT9 1/20 0.41
CYP1A2 P05177 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MAPK1 P28482 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10203555 1.00 L3MBTL1 (0.50) L3MBTL1ALDH1A1TSHRKMT2ALMNA
SCHEMBL14658349 0.95 L3MBTL1 (0.54) L3MBTL1ALDH1A1TSHRKMT2ALMNA
SCHEMBL14658348 0.95 L3MBTL1 (0.54) L3MBTL1ALDH1A1TSHRKMT2ALMNA
SCHEMBL31295019 0.95 L3MBTL1 (0.54) L3MBTL1ALDH1A1TSHRKMT2ALMNA
SCHEMBL30212234 0.84 ALDH1A1 (0.57) L3MBTL1ALDH1A1TSHRKMT2ALMNA
SCHEMBL7201032 0.84 ALDH1A1 (0.57) L3MBTL1ALDH1A1TSHRKMT2ALMNA
SCHEMBL2665681 0.84 L3MBTL1 (0.54) L3MBTL1ALDH1A1TSHRKMT2ALMNA
SCHEMBL9625796 0.84 L3MBTL1 (0.54) L3MBTL1ALDH1A1TSHRKMT2ALMNA
SCHEMBL1332329 0.81 L3MBTL1 (0.55) L3MBTL1ALDH1A1TSHRKMT2ALMNA
SCHEMBL12548927 0.81 L3MBTL1 (0.55) L3MBTL1ALDH1A1TSHRKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004182-B1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LTD (GB) 2013-05-08 EP disclosed
US-20120316202-A1 Compounds which have activity at M1 receptor and their uses in medicine GLAXO GROUP LIMITED 2012-12-13 US disclosed
US-20120041028-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED 2012-02-16 US disclosed
US-20100280071-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2010-11-04 US disclosed
EP-2004182-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2008-12-24 EP disclosed
WO-2007107565-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE GLAXO GROUP LIMITED (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041028-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE CHRM1, CHRM2, CHRM4 L3MBTL1 1083/4885ALDH1A1 299/4885TSHR 491/4885
US-20100280071-A1 BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE CHRM1, CHRM2, CHRM4 L3MBTL1 1083/4885ALDH1A1 299/4885TSHR 491/4885
US-20120316202-A1 Compounds which have activity at M1 receptor and their uses in medicine CHRM1, CHRM2, CHRM5 L3MBTL1 3387/4885ALDH1A1 1046/4885TSHR 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.